ABSTRACT
Tigecycline is a broad-spectrum antibiotic agent used to treat severe or multidrug-resistant (MDR) bacterial infections. Bacterial infection is a common and severe complication or co-morbidity associated with end-stage renal disease (ESRD). However, few cases have been reported regarding the adverse drug reaction of tigecycline in patients with ESRD. Here, we detail the case of a 19-year-old female with ESRD, who received tigecycline to treat sepsis due to a MDR Staphylococcus aureus. Following seven days of tigecycline, the patient developed coagulopathy with hypofibrinogenaemia, although there was no subsequent haemorrhage. The hypofibrinogenaemia resolved within 14 days after discontinuation of tigecycline. Therefore, we recommend that clinicians strictly monitor coagulation parameters in patients with ESRD during tigecycline treatment.
This manuscript has been assigned to a volume and issue but has not yet been published. It is either being edited, typeset or is in the proof stage of publication.
In the pre-published stage, this manuscript may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Any final changes in this manuscript will be made at the time of publication and will be reflected in the final electronic version of the issue. The editors and authors and their respective employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained in the articles in this section.
Our 7 faculties and 12 professional schools offer more than 200 programmes to some 18,000 graduate, undergraduate and continuing studies students.
The UWI, Mona ranks first in Jamaica among accredited tertiary-level programmes. In 2012, the University was again one of Jamaica’s Top 100 Employers.
© Copyright 2014-2026 | Disclaimer | Privacy Statement
